Acadia Pharmaceuticals’ Nuplazid (pimavanserin) — which is being evaluated as a potential treatment for hallucinations and delusions associated…
Articles by Marta Figueiredo, PhD
Eisai and Biogen’s experimental therapy lecanemab (BAN2401) safely leads to rapid and sustained reductions in the brain…
Six months of treatment with GemVax & KAEL’s investigational GV1001 provided benefits in the cognition and daily life…
The U.S. Food and Drug Administration (FDA) has rejected Acadia Pharmaceuticals’ request that Nuplazid (pimavanserin) be the first approved treatment of…
The last participant has completed all predefined assessments in the Phase 3 COGNITE clinical trial, which is assessing the safety…
A simple language test, when combined with an artificial intelligence model, can predict which people will develop Alzheimer’s disease…
People with high blood pressure, or hypertension, during midlife are at a greater risk of developing dementia, irrespective of their…
Increasing evidence places beta-amyloid aggregates at the center of the toxic protein clumps and neuroinflammation that drive Alzheimer’s, two experts…
Continued activity improves physical health in older adults at risk of Alzheimer’s, which in turn can potentially reduce their risk…
Treatment with Anavex‘s investigational therapy Anavex 2-73 significantly reduces cognitive decline in people with Alzheimer’s disease and sustains their…